Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prostate Management Diagnostics Inc.

Latest From Prostate Management Diagnostics Inc.

Prostate Cancer: Dissatisfaction With Current Diagnostics Drives Interest In Innovation

The lack of accurate tools for diagnosing the severity of prostate cancer creates opportunities for start-ups with novel approaches. Profiles of 3D Biopsy, Blue Earth Diagnostics, UroSens, and Prostate Management Diagnostics.

Medical Device

Prostate Management Diagnostics Inc.

Prostate Management Diagnostics Inc. was formed to commercialize research on a series of genetic markers, discovered at The Genome Institute at the Washington University School of Medicine that could help determine whether a prostate cancer is indolent or aggressive in patients newly diagnosed with the disease.

Medical Device

Medtech Execs On The Move, January 2015

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Medical Device

Medical Device Deals Update, January 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced December 2014-January 2015.

Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing